Appeal No. 2007-0542
Application No. 10/301,185
of Appellants’ statements in the application, Lee, and Cronk; and 2) Claims
45-48, 50, 52, and 53 stand rejected under 35 U.S.C. § 103(a) as obvious
over Frey in view of Appellants’ statements in the application, Zakzewski,
and Cronk. Br. 1.
The Examiner relies on the following evidence in rejecting the claims
in this appeal:
Frey U.S. Pat. 5,624,898 Apr. 29, 1997
Lee et al. U.S. Pat. 5,250,023 Oct.05, 1993
Cronk et al. U.S. Pat. 6,244,265 B1 Jun. 12, 2001
Zakzewksi, C.A. et al. “Transdermal delivery of regular insulin to chronic
diabetic rats: effect of skin preparation and electrical enhancement,” Journal
of Controlled Release, Vol. 50 ppp.267-272 (1998)
CLAIMS
For the purpose of deciding this appeal, we select claim 45 as
representative of the appealed claims. It reads as follows:
45. A method for delivering a neurologic agent to the central
nervous system of a mammal in need of treatment for a central
nervous system disorder, said method comprising transdermally
administering a composition comprising said neurologic agent
at a region of the skin of a mammal that is innervated by the
trigeminal nerve and outside the nasal cavity of the mammal,
said neurologic agent selected the group consisting of a nerve
growth factor and a fibroblast growth factor.
ISSUE
The Examiner contends that the prior art teaching of administration of
NGF and FGF through the nasal cavity would have led the skilled worker to
administer these agents transdermally to skin regions innervated by the
2
Page: Previous 1 2 3 4 5 6 7 Next
Last modified: September 9, 2013